Core Insights - ICF has been awarded a multi-million dollar contract amendment by Southern California Edison (SCE) to expand its role in the Agricultural Energy Efficiency Program (AgEE Program), significantly increasing its involvement in the agricultural sector [1] - The expansion aims to help agricultural customers reduce energy costs and improve operational efficiencies through rebates and advanced analytical tools [1] - ICF will utilize its ICF Sightline® platform to process rebates and engage customers, enhancing the program's reach and effectiveness [1] Company Overview - ICF is a leading global solutions and technology provider with approximately 9,000 employees, specializing in energy efficiency, electrification, and demand management programs [1] - The company collaborates with public and private sector clients to navigate complex challenges and implement cost-effective energy-saving programs [1] Program Details - The AgEE Program is designed to assist farms, dairies, greenhouses, and horticulture facilities in targeting high-energy usage and adopting advanced technologies [1] - ICF's partnership with SCE aims to deepen trust with agricultural customers while addressing challenges such as evolving regulations and rising operational costs [1]

Core Insights - Harmonic Inc. reported strong quarterly bookings in its Broadband business, achieving a book-to-bill ratio of 3.5 in Q4 2025, indicating robust demand and a significant year-over-year increase in backlog, which enhances visibility for 2026 [1][2] - The company anticipates strong revenue growth in Broadband driven by Unified DOCSIS 4.0 deployments and large customer plans, while the Video business, now classified as discontinued operations, exceeded revenue and profitability expectations [1][2] - Harmonic is on track to complete the sale of its Video business for $145 million in cash, expected to close in Q2 2026, which will support its capital allocation priorities [1][2] Financial Highlights - Total net revenue for Q4 2025 was $157.3 million, with a net loss per share of $0.49 [1][2] - For the Broadband segment, Q4 2025 net revenue was $98.2 million, with a net income of $0.2 million, and adjusted EBITDA of $12.1 million [1][2] - The company repurchased approximately 1.3 million shares for $13.3 million in Q4 2025, and cash reserves increased to $124.1 million from $101.5 million year-over-year [1][2] Business Operations - The backlog and deferred revenue reached $573.8 million, a 73% increase from $332.3 million the previous year, with a current portion of $307 million, reflecting a 110% year-over-year growth [1][2] - Harmonic achieved record bookings in the Rest-of-World segment in Q4, indicating potential for continued revenue growth in 2026 and beyond [1][2] - The company has signed several multi-year contracts, showcasing long-term commitment and revenue stability [1][2] Financial Guidance - For Q1 2026, Harmonic projects GAAP net revenue between $100 million and $105 million, with a gross margin of 53.0% to 54.3% [2][7] - For the full year 2026, the company anticipates GAAP net revenue between $440 million and $480 million, with a gross margin of 50.5% to 52.5% [2][7] - Non-GAAP guidance for Q1 2026 includes a net income per share estimate of $0.11 to $0.12, while for FY 2026, it is projected at $0.46 to $0.63 [2][7]

Core Viewpoint - W. P. Carey Inc. has successfully closed a public offering of 6,000,000 shares of common stock, generating gross proceeds of $432 million, with plans to utilize the funds for future investments, debt repayment, and general corporate purposes [1] Group 1: Offering Details - The offering included a 30-day option for underwriters to purchase an additional 900,000 shares [1] - The company entered into forward sale agreements with Bank of America and JPMorgan Chase, allowing for the borrowing and selling of shares to underwriters [1] - The expected physical settlement of the forward sale agreements will occur within approximately 24 months from the date of the prospectus supplement [1] Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund potential future investments, repay certain indebtedness, and for general corporate purposes [1] - The company has an unsecured revolving credit facility that may be repaid using the proceeds [1] Group 3: Company Profile - W. P. Carey Inc. is an internally-managed, diversified REIT primarily focused on owning commercial real estate, with a significant portion of revenue derived from lease income [1] - The company's real estate portfolio mainly consists of single-tenant industrial, warehouse, and retail facilities critical to tenant operations [1]

10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference [Accessibility Statement] Skip NavigationPLEASANTON, Calif., Feb. 19, 2026 /PRNewswire/ -- [10x Genomics, Inc.](Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, at 11:50 a.m. Eastern Time.Interested parties may access a live webcast of the fireside chat on the "I ...

CARMEL, Ind., Feb. 19, 2026 /PRNewswire/ -- Merchants Bancorp ("Merchants") (Nasdaq: MBIN), parent company and registered bank holding company of Merchants Bank of Indiana ("Merchants Bank"), today announced that its Board of Directors declared the following quarterly cash dividends for the first quarter of 2026, in each case to shareholders of record on March 13, 2026, payable on April 1, 2026: A dividend of $0.11 per share on the Company's outstanding shares of its common stock (NASDAQ:MBIN); A dividend o ...

Tyra Biosciences to Participate in Upcoming Investor Conferences [Accessibility Statement] Skip NavigationCARLSBAD, Calif., Feb. 19, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences:36th Annual Oppenheimer Life Sciences Healthcare ConferenceFormat: Vi ...

Core Insights - GRAIL, Inc. reported significant commercial growth in 2025, with total revenue increasing by 17% year-over-year to $147.2 million and U.S. Galleri revenue growing by 26% to $136.8 million [1][4] - The company completed its Premarket Approval (PMA) submission to the FDA for the Galleri test and shared positive topline results from the NHS-Galleri trial, indicating a substantial reduction in Stage IV cancer diagnoses [1][2] - GRAIL's financial position remains strong, with cash and cash equivalents totaling $904.4 million as of December 31, 2025, providing financial flexibility for future growth [1][4] Financial Performance - For Q4 2025, total revenue was $43.6 million, a 14% increase year-over-year, while U.S. Galleri revenue reached $41.3 million, up 31% [1][4] - The net loss for Q4 2025 was $99.2 million, which includes $34.6 million in amortization related to the Illumina acquisition [1][4] - For the full year 2025, the net loss was $408.4 million, an improvement of $1.6 billion or 80% compared to the previous year [1][4] Business Highlights - GRAIL expanded access to the Galleri test through partnerships with digital health platforms, including the launch of the Hims & Hers Multi-Cancer Test [1][2] - The company completed the analysis of the full 35,000 participant PATHFINDER 2 study, demonstrating consistent performance with earlier results [1][2] - The NHS-Galleri trial results showed that adding Galleri to standard care screening significantly increased the detection rates of early-stage cancers [1][2] Cash Position - As of December 31, 2025, GRAIL had cash, cash equivalents, and short-term marketable securities totaling $904.4 million, ensuring operational sustainability into 2030 [1][4] Future Outlook - GRAIL anticipates continued commercial growth in 2026, with plans for new partnerships in digital health and further integration into health systems [1][2] - Detailed results from the PATHFINDER 2 and NHS-Galleri trials are expected to be presented in mid-2026 [1][2]

Core Insights - The NHS-Galleri trial demonstrated a significant reduction in Stage IV cancer diagnoses and an increase in the detection of Stage I and II cancers, although the primary endpoint of statistically significant reduction in Stage III-IV cancers was not met [1][2] Group 1: Trial Results - The Galleri test led to a substantial reduction in cancers detected through emergency presentations, which are linked to higher mortality and healthcare costs [1] - There was a notable increase in the absolute number of Stage I-II cancers among 12 pre-specified deadly cancer types in the intervention group [1] - The overall cancer detection rate improved four-fold when Galleri was added to standard care screening compared to standard care alone for breast, colorectal, cervical, and high-risk lung cancers [1] - A clinically meaningful reduction in Stage IV diagnoses was observed, with over a 20% decrease in the second and third rounds of sequential screening for the specified group of cancers [1][2] Group 2: Trial Design and Objectives - The NHS-Galleri trial is the largest randomized controlled trial assessing a multi-cancer early detection test, involving over 142,000 participants aged 50 to 77 [2] - The primary objective was to show a reduction in late-stage (III-IV) cancers in those receiving the Galleri test compared to those who did not [2] - Secondary objectives included evaluating the performance of the Galleri test, safety, and healthcare resource utilization [2] Group 3: Company and Product Information - GRAIL, Inc. focuses on early cancer detection using next-generation sequencing and machine learning to identify multiple cancer types at earlier stages [2] - The Galleri test can detect over 50 types of cancer through a simple blood draw, significantly increasing the number of cancers detected when used alongside standard screenings [2] - The test is recommended for adults aged 50 or older with an elevated risk for cancer and has the lowest false positive rate among multi-cancer early detection tests [2]

measures. In particular, the non-GAAP R&D and SG&A expense financial measures exclude non-cash, stock- based compensation expense. These non-GAAP financial measures are provided as a complement to financial measures reported in accordance with GAAP because management uses these non-GAAP financial measures when assessing and identifying operational trends. In management's opinion, these non-GAAP financial measures are useful to investors and other users of PTC's financial statements by providing greater tran ...

Synopsys Appoints Former Deloitte Executive Peter Shimer to Board of Directors and Announces Board Transitions [Accessibility Statement] Skip NavigationSUNNYVALE, Calif., Feb. 19, 2026 /PRNewswire/ -- [Synopsys], Inc. (NASDAQ: SNPS) today announced the appointment of Peter A. Shimer to its board of directors. Shimer brings four decades of experience at international public accounting firm Deloitte where he held numerous executive roles, including serving as its interim chief executive officer (CEO). During ...